

Applicants Philip O. Livingston and Friedhelm Helling  
Serial No. : 08/196,154 Group Art Unit: 1642  
Filed : November 16, 1995 Examiner: A. Holleran  
For : GANGLIOSIDE-KLH CONJUGATE VACCINE PLUS QS-21

Assistant Commissioner for Patents  
Washington, D.C. 20231

March 31, 2003

S I R:

Transmitted herewith is an amendment to the above identified application.

☒ Small entity status of this application under 37 C.F.R. \$1.9 and \$1.27 has been established by a verified statement previously submitted.

☐ A verified statement to establish small entity status under 37 C.F.R. \$1.9 and \$1.27 is enclosed.

☒ No additional fee is required.

RECEIVED  
APR 07 2003

The filing fee is calculated as follows:

TECH CENTER 1600/2900

	NUMBER AFTER AMEND- MENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE FEE				
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
Total Claims	25	-	32	=	0	X	\$9	\$18	=	0	0
Indepen- dent Claims	5	-	13	=	0	X	\$42.00	\$84.00	=	0	0
Multiple Dependent Claim(s) Presented _____ Yes <input checked="" type="checkbox"/> No For First Time							\$140	\$280	0	0	0
							TOTAL ADDITIONAL FEE \$ 0				

\*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\*If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

Applicants: Philip O. Livingston and Friedhelm Helling  
Serial No.: 08/196,154  
Filed : November 16, 1995

Amendment Transmittal Letter  
Page Two

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment of the number of claims as originally filed

\_\_\_\_ Please charge Deposit Account No. 03-3125 in the amount of \$ \_\_\_\_\_. Three copies of this sheet is enclosed.

\_\_\_\_ A check in the amount of \$ \_\_\_\_ is enclosed.

X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposition Account No. 03-3125. Three copies of this sheet are enclosed.

X Any filing fees under 37 C.F.R. \$1.16 for the presentation of extra claims.

X Any patent application processing fees under 37 C.F.R. \$1.17.

Respectfully submitted,

Mark A. Farley


John P. White  
Registration No. 28,678  
Mark A. Farley  
Registration No. 33,170  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

Mark A. Farley 3/31/03  
Date

John P. White  
Reg. No. 28,678  
Mark A. Farley  
Reg. No. 33,170



Dkt. 43016-A-PCT-US/JPW/MAF

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Philip O. Livingston and Friedhelm Helling  
Serial No.: 08/196,154 Examiner: Anne Holleran  
Filed : November 16, 1995 Group Art Unit: 1642  
For : GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21

#  
36/3  
KD  
41003

1185 Avenue of the Americas  
New York, New York 10036  
March 31, 2003

**RECEIVED**

Assistant Commissioner for Patents  
Washington, D.C. 20231

APR 07 2003

SIR:

TECH CENTER 1600/2900

**AMENDMENT IN RESPONSE TO DECEMBER 31, 2002 OFFICE ACTION**

This Amendment is filed in response to the December 31, 2002 Office Action issued by the Patent and Trademark Office in connection with the above-identified application. A response to the Office Action is due on March 31, 2003. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

In the Claims

Cancel claims 97, 101-111 and 113-118 without prejudice or disclaimer.

{ Please add the following new claims 119-143. }

--119. (New) A composition which comprises:

51 a) a conjugate comprising (i) a GM2 ganglioside derivative which comprises an unaltered